BioStock: PHI’s CEO comments on the approved US listing
![](https://phiab.com/wp-content/uploads/2024/08/Biostock-PHI-CEO-comments-on-the-approved-US-listing.jpg)
Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.
Read the full interview with Patrik Eschricht on biostock.se.
Further reading
![Swiss-based Altium major investor BioStock](https://phiab.com/wp-content/uploads/2023/03/Suisse_PHI-320x180.jpg)
BioStock: PHI catches eye of major investor
BioStock contacted Altium’s CEO Goran Dubravcic to learn more about their incentives to invest in PHI.
![Patrik Eschricht and Peter Egelberg shaking hands](https://phiab.com/wp-content/uploads/2023/02/20230118-Peter-and-Patrik_web-320x180.jpg)
BioStock: PHI comments on the new senior positions in the company
BioStock reached out to Patrik Eschricht and Peter Egelberg to better understand the background behind the recent management shift.
![PHI CSO Kersti Alm at Biostock](https://phiab.com/wp-content/uploads/2022/11/Kersti-640x353-1-320x180.jpg)
BioStock: PHI on the alliance for cell-based biomanufacturing
Kersti Alm, CSO at PHI, visited BioStock’s studio to talk about the recently created alliance for advancing cell-based biomanufacturing and PHI’s pivotal role in the collaboration.
![PHI part of new regenerative medicine alliance](https://phiab.com/wp-content/uploads/2022/11/biostock-PHI-part-of-new-regenerative-medicine-alliance-320x180.jpg)
BioStock: PHI part of new regenerative medicine alliance
BioStock contacted Product Manager Lisa Lindström to learn more about PHI’s newly formed technology development alliance for regenerative medicine and what excites her about the future.